NCT05256446: AMG 701 Expanded Access Program AMG 701 Expanded Access Program Expanded access requests for AMG 701 may be considered for...

IFM 2020-02 MInimal Residual Disease Adapted Strategy (MIDAS) Isa-KRd NCT04934475: Phase 3 - IFM 2020-02 -MInimal Residual Disease...

Pavurutamab NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma...

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma Relapsed & Refractory Myeloma NCT04822337:...

IsKPd - IFM2018-03 NCT04287855: Phase 2: Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in...

The ADVANCE trial Dara-KRd KRd VRd NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With...

NCT04430894: Phase 2: KRDI in Transplant-Eligible MM KRDI in Transplant-Eligible MM This research study is testing the efficacy of an...

(IsKia TRIAL) (IsKia) - (EMN24/HOVON503) NCT04483739: Phase 3: Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for...

NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM Dara-KPd This research study is studying the...

NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)...

A.R.R.O.W.2 NCT03859427: Phase 3: A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and...

NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma Denosumab for Smoldering Multiple Myeloma This study will assess the...

Dara-KRd NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed...

AMG 420 To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous...

Multiple Myeloma Research Consortium NCT03773107: Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for...

Myeloma XI The purpose of this study is to compare a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide...

NCT03756896: Phase 2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma KPd Carfilzomib,...

Multiple Myeloma Research Consortium phase 2 study Dara-KRd NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose...

Phase 3 CANDOR study Dara-Kd Kd Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple...

MASTER TRIAL Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER) Dara-KRd Monoclonal...

NCT02891811: Phase 2: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono...

AMG 176 NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML AMG 176 First in Human Trial in...

NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma...

Multiple Myeloma Research Consortium NCT02332850: Phase Ib Study of SAR650984 With Carfilzomib for Treatment of Relapsed Multiple Myeloma...

GEM-CESAR trial PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en...

NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma A Phase 1 Study in Subjects With Relapsed or...

Phase 3 A.R.R.O.W. trial - ARROW Kd The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib...

An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of...

Cardamon Study KCd Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma (Cardamon) The Cardamon...

CHAMPION 2 NCT01980589: Phase 1: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly...

NCT01775553: Phase 2: Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib The...

CHAMPION Kd A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma (CHAMPION 1) The study had...

The ENDEAVOR Trial KD Vs Vd The primary objective of this study was to compare progression-free survival in patients with multiple...

NCT01464034: Phase 1/2: A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or...

NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease NCT01410500:...

NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients KRd Carfilzomib is an experimental...

THE ASPIRE TRIAL Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in...

NCT01029054: Phase 1/2: Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple...

RRMM Relapsed and Refractory Multiple Myeloma NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma...